, Volume 69, Issue 4, pp 449–459 | Cite as


In Partial-Onset Seizures
  • Sarah A. Cross
  • Monique P. Curran
Adis Drug Profile


  • ▴ Lacosamide is a functionalized amino acid, the antiepileptic effects of which appear to be due to a novel mode of action, namely the selective enhancement of slow inactivation of voltage-gated sodium channels.

  • ▴ Lacosamide is available as oral or intravenous formulations. Bioequivalence between the oral tablet and the oral syrup of lacosamide has been established. The bioavailability of the oral lacosamide tablet was similar to that of a 30- or 60-minute intravenous infusion of lacosamide administered at the same dosage.

  • ▴ Oral lacosamide when added concomitantly with between one and three antiepileptic drugs was effective in adult patients with uncontrolled partialonset seizures with or without secondary generalization, according to pooled data (n= 1308) from three phase II/III studies that had a 12-week maintenance phase. The percentage of patients with a ≥50% reduction from baseline to the maintenance phase in seizure frequency was significantly greater with oral lacosamide 200 or 400 mg/day (34% and 40%) than with placebo (23%).

  • ▴ The median percentage reduction in seizure frequency per 28 days from baseline to the maintenance phase was significantly greater with lacosamide 400 mg/day than with placebo in each of the three phase II/III studies.

  • ▴ Lacosamide was generally well tolerated in adult patients with partial-onset seizures, with most treatment-emergent adverse events being of mild or moderate severity. Dizziness was the most common treatment-related adverse event. When used as short-term replacement for oral lacosamide, intravenous lacosamide was well tolerated when administered as a 15-, 30- or 60-minute infusion.


Seizure Frequency Lacosamide Median Percentage Reduction Adis Drug Profile Oral Lacosamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    UK National Institute for Clinical Excellence. Technology appraisal guidance 76: newer drugs for epilepsy in adults [online]. Available from URL: [Accessed 2007 Feb 27]
  2. 2.
    Ben-Menachem E, Henriksen O, Johannessen SI. Diagnosis and treatment of partial seizures. CNS Drugs 1999 Jan; 11(1): 23–39CrossRefGoogle Scholar
  3. 3.
    Johannessen SI, Ben-Menachem E. Management of focalonset seizures: an update on drug treatment. Drugs 2006; 66(13): 1701–25PubMedCrossRefGoogle Scholar
  4. 4.
    Johannessen Landmark C, Johannessen SI. Pharmacological management of epilepsy: recent advances and future prospects. Drugs 2008; 68(14): 1925–35PubMedCrossRefGoogle Scholar
  5. 5.
    Devinsky O. Patients with refractory seizures. N Engl J Med 1999 May 20; 340(20): 1565–70PubMedCrossRefGoogle Scholar
  6. 6.
    European Medicines Agency. Lacosamide (Vimpat®): summary of product characteristics [online]. Available from URL: [Accessed 2008 Nov 5]
  7. 7.
    Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008 Jan; 44(1): 35–40CrossRefGoogle Scholar
  8. 8.
    Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurother 2007 Jan; 4(1): 145–8CrossRefGoogle Scholar
  9. 9.
    US FDA. Vimpat® (lacosamide) tablets and injection: US prescribing information [online]. Available from URL: [Accessed 2008 Oct 30]
  10. 10.
    Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007 Spring; 13(1): 21–42PubMedCrossRefGoogle Scholar
  11. 11.
    Errington AC, Stöhr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008 Jan; 73(1): 157–69PubMedCrossRefGoogle Scholar
  12. 12.
    Czech T, Yang J, Csaszar E, et al. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 2004; 29(12): 2189–96PubMedCrossRefGoogle Scholar
  13. 13.
    Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002 Sep; 51(1–2): 31–71PubMedCrossRefGoogle Scholar
  14. 14.
    Errington AC, Coyne L, Stöhr T, et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006 Jun; 50(8): 1016–29PubMedCrossRefGoogle Scholar
  15. 15.
    Stöhr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007 Apr 11; 74(2–3): 147–54PubMedCrossRefGoogle Scholar
  16. 16.
    Biomedical systems. Thorough QT trials [online]. Available from URL: [Accessed 2009 Mar 13]
  17. 17.
    Horstmann R, Zisowsky J, Thomas D. Lacosamide demonstrates no potential for QTc-prolongation [abstract no. p245]. Epilepsia 2007 Oct; 48 Suppl. 7: 107Google Scholar
  18. 18.
    European Medicines Agency. Assessment report for Vimpat (lacosamide) [online]. Available from URL: [Accessed 2008 Oct 3]
  19. 19.
    Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004; 61(1–3): 1–48PubMedCrossRefGoogle Scholar
  20. 20.
    Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927 [abstract no. 2.342]. Epilepsia 2004; 45 Suppl. 7: 307Google Scholar
  21. 21.
    Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927 [abstract no. 2.174]. Epilepsia 2002; 43 Suppl. 7: 188Google Scholar
  22. 22.
    Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partialonset seizures. Epilepsia 2007 May 23; 48(7): 1308–17PubMedCrossRefGoogle Scholar
  23. 23.
    Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008 Mar; 49(3): 418–24PubMedCrossRefGoogle Scholar
  24. 24.
    Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender [abstract no. 2.361]. Epilepsia 2004; 45 Suppl. 7: 313Google Scholar
  25. 25.
    Hortsmann R, Bonn R, Cawello W, et al. SPM 927 does not interact with valproic acid and carbamazepine [abstract no. 1.271]. Epilepsia 2003; 44 Suppl. 9: 97Google Scholar
  26. 26.
    Schiltmeyer B, Thomas D, Horstmann R, et al. Lacosamide has no potential for interaction with metformin [abstract no. P869]. Diabet Med 2006 Dec 1; 23 Suppl. 4: 315–6Google Scholar
  27. 27.
    Thomas D, Scharfenecker U, Schiltmeyer B, et al. Low potential for drug-drug interaction of lacosamide [abstract no. 2.235]. Epilepsia 2006; 47 Suppl. 4: 200Google Scholar
  28. 28.
    Haläsz P, Kälviäinen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. Epub 2009 Jan 17Google Scholar
  29. 29.
    Chung S, Sperling M, Biton V, et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures [abstract P02.097]. 60th Annual Meeting of the American Academy of Neurology; 2008 Apr 12–19, Chicago (IL)Google Scholar
  30. 30.
    International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy 1981; 22(4): 489–501Google Scholar
  31. 31.
    US National Institutes of Health. Assess safety and efficacy of lacosamide in patients with partial seizures (SP774) [online]. Available from URL: [Accessed 2008 Oct 8]
  32. 32.
    US National Institutes of Health. Determine safety and efficacy of long-term oral lacosamide in patients with partial seizures (SP756) [online]. Available from URL: [Accessed 2008 Oct 8]
  33. 33.
    US National Institutes of Health. To determine tolerability and efficacy of long-term oral lacosamide in patients with partial seizures (SP615) [online]. Available from URL: [Accessed 2008 Oct 3]
  34. 34.
    Rosenfeld W, Fountain NB, Kaubrys G, et al. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract no. 3.191]. Epilepsia 2007; 48 Suppl. 6: 318–9Google Scholar
  35. 35.
    Biton V, Fountain N, Rosenow F, et al. Safety and tolerability of lacosamide: summary of adverse events [abstract and poster]. Eight European Congress on Epileptology; 2008 Sep 21–25; BerlinGoogle Scholar
  36. 36.
    Krauss G, Ben-Menachem E, Mameniskiene R, et al. Safety, tolerability, and pharmacokinetic parameters of 10-, 15- and 30-minute intravenous infusions as short-term replacement therapy in subjects with partial onset seizures [abstract no. S45.008]. 60th Annual Meeting of the American Academy of Neurology; 2008 Apr 12–19; Chicago (IL)Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthPhiladelphiaUSA

Personalised recommendations